We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

CorMedix Inc (CRMD) USD0.001

Sell:$3.26 Buy:$3.32 Change: $0.04 (1.23%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.04 (1.23%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.04 (1.23%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on developing its product DefenCath, which is an antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic emodialysis. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters CVCs in clinical settings, such as hemodialysis, total parenteral nutrition and oncology. In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Contact details

300 Connell Drive, Suite 4200
United States
+1 (908) 5179500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$179.78 million
Shares in issue:
54.81 million
United States
US dollar

Key personnel

  • Joseph Todisco
    Chief Executive Officer, Director
  • Matthew David
    Chief Financial Officer, Executive Vice President
  • Elizabeth Massonhurlburt
    Executive Vice President, Head of Clinical and Medical Affairs
  • Erin Mistry
    Executive Vice President, Chief Commercial Officer
  • Phoebe Mounts
    Executive Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.